Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I. Pacey S, et al. Among authors: de bono js. Clin Cancer Res. 2011 Mar 15;17(6):1561-70. doi: 10.1158/1078-0432.CCR-10-1927. Epub 2011 Jan 28. Clin Cancer Res. 2011. PMID: 21278242 Free PMC article. Clinical Trial.
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
Calvo E, Tolcher AW, Hammond LA, Patnaik A, de Bono JS, Eiseman IA, Olson SC, Lenehan PF, McCreery H, Lorusso P, Rowinsky EK. Calvo E, et al. Among authors: de bono js. Clin Cancer Res. 2004 Nov 1;10(21):7112-20. doi: 10.1158/1078-0432.CCR-04-1187. Clin Cancer Res. 2004. PMID: 15534081 Clinical Trial.
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. White CL, et al. Among authors: de bono js. Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6. Gene Ther. 2008. PMID: 18323793 Clinical Trial.
NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer growth.
Welti J, Bogdan D, Figueiredo I, Coleman I, Jiménez Vacas J, Liodaki K, Weigl F, Buroni L, Zeng W, Bernett I, Bertan C, Roumeliotis TI, Bhamra A, Rekowski J, Gurel B, Neeb AJ, Ning J, Li D, Gil VS, Riisnaes R, Miranda S, Crespo M, Ferreira A, Tunariu N, Pasqua E, Chessum N, Cheeseman M, Te Poele R, Powers M, Carreira S, Choudhary J, Clarke P, Banerji U, Swain A, Jones K, Yuan W, Workman P, Nelson PS, de Bono JS, Sharp A. Welti J, et al. Among authors: de bono js. Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386. Online ahead of print. Clin Cancer Res. 2025. PMID: 39787247
Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.
Herrmann K, Gafita A, de Bono JS, Sartor O, Chi KN, Krause BJ, Rahbar K, Tagawa ST, Czernin J, El-Haddad G, Wong CC, Zhang Z, Wilke C, Mirante O, Morris MJ, Fizazi K. Herrmann K, et al. Among authors: de bono js. EClinicalMedicine. 2024 Oct 4;77:102862. doi: 10.1016/j.eclinm.2024.102862. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39430616 Free PMC article.
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).
Gillessen S, Turco F, Davis ID, Efstathiou JA, Fizazi K, James ND, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Zilli T, Agarwal N, Antonarakis ES, Aparicio A, Armstrong AJ, Bastos DA, Attard G, Axcrona K, Ayadi M, Beltran H, Bjartell A, Blanchard P, Bourlon MT, Briganti A, Bulbul M, Buttigliero C, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Clarke CS, Clarke N, de Bono JS, De Santis M, Duran I, Efstathiou E, Ekeke ON, El Nahas TIH, Emmett L, Fanti S, Fatiregun OA, Feng FY, Fong PCC, Fonteyne V, Fossati N, George DJ, Gleave ME, Gravis G, Halabi S, Heinrich D, Herrmann K, Hofman MS, Hope TA, Horvath LG, Hussain MHA, Jereczek-Fossa BA, Jones RJ, Joshua AM, Kanesvaran R, Keizman D, Khauli RB, Kramer G, Loeb S, Mahal BA, Maluf FC, Mateo J, Matheson D, Matikainen MP, McDermott R, McKay RR, Mehra N, Merseburger AS, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Mutambirwa SBA, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Renard-Penna R, Ryan CJ, Saad F, Sade JP, Sandhu S, Sartor OA, Schaeffer E, Scher HI, Sharifi N, Skoneczna IA, Soule HR, Spratt DE, Srinivas S, Sternberg CN, S… See abstract for full author list ➔ Gillessen S, et al. Among authors: de bono js. Eur Urol. 2024 Oct 10:S0302-2838(24)02610-1. doi: 10.1016/j.eururo.2024.09.017. Online ahead of print. Eur Urol. 2024. PMID: 39394013 Free article.
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K; PSMAfore Investigators. Morris MJ, et al. Among authors: de bono js. Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15. Lancet. 2024. PMID: 39293462 Clinical Trial.
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, Welti J, Sharp A, Ryan NK, Knudsen LA, Schiewer MJ, DeArment EG, Janas T, Su XA, Butler LM, de Bono JS, Frese K, Brooks N, Pegg N, Knudsen KE, Shafi AA. Sardar S, et al. Among authors: de bono js. Oncogene. 2024 Oct;43(43):3197-3213. doi: 10.1038/s41388-024-03148-4. Epub 2024 Sep 13. Oncogene. 2024. PMID: 39266679 Free PMC article.
522 results